Clinical Trials Logo

Uveal Neoplasms clinical trials

View clinical trials related to Uveal Neoplasms.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04879017 Terminated - Clinical trials for Metastatic Uveal Melanoma

FHD-286 in Subjects With Metastatic Uveal Melanoma

Start date: May 11, 2021
Phase: Phase 1
Study type: Interventional

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

NCT ID: NCT04589832 Terminated - Uveal Melanoma Clinical Trials

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Start date: January 11, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1 (PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle). Entrectinib (PO) will be given daily on Days 1 through 28 of each cycle. Response will be evaluated after every 2 cycles. Treatment will continue until disease progression based on RECIST criteria or intolerable toxicity.

NCT ID: NCT02831933 Terminated - Clinical trials for Metastatic Uveal Melanoma

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

ENSIGN
Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before nivolumab in patients with metastatic squamous or non-squamous non-small cell lung carcinoma (NSCLC) and metastatic uveal melanoma. In situ gene therapy will consist of adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk) plus Valacyclovir therapy.

NCT ID: NCT02743611 Terminated - Clinical trials for Acute Myeloid Leukemia

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Start date: April 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.

NCT ID: NCT02601378 Terminated - Uveal Melanoma Clinical Trials

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Start date: February 1, 2016
Phase: Phase 1
Study type: Interventional

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.

NCT ID: NCT02359851 Terminated - Clinical trials for Stage IV Uveal Melanoma

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Start date: May 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with uveal melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.

NCT ID: NCT02336763 Terminated - Iris Melanoma Clinical Trials

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Start date: October 2014
Phase: N/A
Study type: Interventional

This clinical trial studies giving radiation therapy to the liver in patients with uveal (eye) melanoma who have a specific chromosome loss (monosomy 3) or are DecisionDx Class 2 and therefore more likely to have their disease spread from the eye to the liver. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Early radiation to the liver may reduce the development of tumors in the liver and the overall risk of disease recurrence.

NCT ID: NCT01801358 Terminated - Uveal Melanoma Clinical Trials

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma. Cohorts of 3-6 patients will be assessed for dose limiting toxicities (DLTs) during Cycle 1 until the maximum tolerated dose (MTD) of the combination therapy is determined. The MTD or Phase 2 Recommended Dose (P2RD) will be used in a Phase II part of the study, which will enrol 55 patients each into two randomized groups: the combination therapy or MEK162 alone. The Phase II part will continue until proof of concept is established. Patients will continue treatment as long as clinical benefit is seen and no limiting adverse toxicity is observed

NCT ID: NCT01730157 Terminated - Liver Metastases Clinical Trials

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Start date: December 2012
Phase: Phase 0
Study type: Interventional

This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radioembolization together with ipilimumab may kill more tumor cells in patients with uveal melanoma

NCT ID: NCT01533948 Terminated - Stage IV Melanoma Clinical Trials

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.